

18 November 2014

### December 2014 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **December 2014** Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) if you want to change or remove your contact details.

#### New listings

- Insulin aspart (NovoRapid FlexPen) inj 100 u per ml, 3 ml syringe (p'code 2469952)
- Isoprenaline (Isuprel) inj 200 mcg per ml, 1 ml ampoule (p'code 2461544)
- Imiquimod (Apo-Imiquimod Cream 5%) crm 5%, 250 mg sachet – Special Authority – Retail pharmacy (p'code 2470993)
- Citalopram hydrobromide (Celapram) tab 20 mg – Brand Switch Fee payable (p'code 2115786)
- Imatinib mesilate (Imatinib-AFT) cap 400 mg – No patient co-payment payable (p'code 2466252)
- Cetirizine hydrochloride (Histaclear) oral liq 1 mg per ml (p'code 2461625)
- Pharmacy services (BSF Zypine) brand switch fee – may only be claimed once per patient (p'code 2470438)
- Pharmacy services (BSF Quetapel) brand switch fee – may only be claimed once per patient (p'code 2470446)
- Pharmacy services (BSF Risperon) brand switch fee – may only be claimed once per patient (p'code 2470454)
- Pharmacy services (BSF Capecitabine Winthrop) brand switch fee – may only be claimed once per patient (p'code 2470462)
- Pharmacy services (BSF Celepram) brand switch fee – may only be claimed once per patient (p'code 2471558)

#### Changes to restrictions, chemical names and presentations

- Docusate sodium with sennosides (Laxsol) tab 50 mg with sennosides 8 mg – amended presentation description
- Prednisolone (Redipred) oral liq 5 mg per ml – amended chemical description
- Zoledronic acid (Aclasta) inj 5 mg per 100 ml, vial – amended presentation description
- Olanzapine tab 2.5 mg, 5 mg and 10 mg (Zypine) and tab orodispersible 5 mg and 10 mg (Zypine ODT) – addition of Brand Switch Fee
- Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – addition of Brand Switch Fee
- Risperidone (Risperon) oral liq 1 mg per ml – addition of Brand Switch Fee
- Capecitabine (Capecitabine Winthrop) tab 150 mg and 500 mg – addition of Brand Switch Fee
- Methotrexate (Trexate) tab 2.5 mg and 10 mg – removal of Brand Switch Fee
- Imatinib mesilate tab 100 mg (Glivec), and cap 100 mg and 400 mg (Imatinib-AFT) – note moved to chemical level
- Inhaled long-acting beta-adrenoceptor agonists – removal of Prescribing Guideline

**Increased subsidy**

Chemical	Presentation	Fully subsidised brands
Erythromycin ethyl succinate	Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml	E-Mycin E-Mycin
Tretinoin	Cap 10 mg	Vesanoid

**Decreased subsidy**

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Amlodipine	Tab 2.5 mg	Apo-Amlodipine	
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet*	Ginet 84
Docetaxel	Inj 1 mg for ECP	Baxter	
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg	Laxsol	
Donepezil hydrochloride	Tab 5 mg and 10 mg	Donepezil-Rex	
Finasteride	Tab 5 mg	Finpro*	Rex Medical
Glycerol	Liquid	healthE Glycerol BP*	healthE
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine (Relieve), 1,000 tab pack *	Paracetamol + Codeine (Relieve), 100 tab pack
Potassium iodate	Tab 256 mcg (150 mcg elemental iodine)		NeuroKare
Prednisolone	Oral liq 5 mg per ml	Redipred	
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	

\* no subsidy changes for these brands for 1 December 2014.

Pharmacists – let us know if you would prefer to receive the dispatch and pharmacy notifications via email rather than fax. Please call 0800 66 00 50, option 1.